INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.

Aim: The purpose of this study is to evaluate the efcacy and safety prole of intravitreal injection of bevacizumab for macular edema secondary to retinal vein occlusion. A prospective analysis w Methods: as conducted on patients with macular edema because of retinal vein occlusion, who had been administered three doses of intravitreal injections of bevacizumab at four weeks interval and further retreatment was based on optical coherence tomography (OCT) ndings. The changes in the retinal thickness and visual acuity were evaluated to judge the efcacy, and adverse events were noted for the safety prole over a period of 6 months. A total of 37 Results: eyes of thirty seven patients were included in the study. The mean age of the patients was 59 ± 14 years. The mean pre-injection best corrected visual acuity (BCVA) was 1.14± 0.48 log minimum angle of resolution (logMAR) and central foveal thickness (CFT)of 449.8 ± 115.22μm, and the post-injection BCVA at 6 months was 0.51 ± 0.36 logMAR with a CFT of259.9 ± 87.08μm, this change was statistically signicant (P < 0.05). During the follow-up period after injection, no patient had inammation, endophthalmitis, an increase in intra-ocular pressure, or systemic side effects. Intravitreal bevacizumab appears to be a safe and effective Conclusion: treatment in patients with macular edema secondary to retinal vein occlusion.